ImmunoCellular Therapeutics Ltd (IMUC) Short Interest Update

ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 2,403,971 shares, a growth of 6.3% from the January 12th total of 2,260,706 shares. Based on an average daily trading volume, of 1,251,998 shares, the days-to-cover ratio is currently 1.9 days. Currently, 6.8% of the company’s stock are sold short.

Shares of ImmunoCellular Therapeutics (NYSEAMERICAN IMUC) traded down $0.01 during trading on Friday, reaching $0.22. The company’s stock had a trading volume of 2,925,385 shares, compared to its average volume of 1,381,313. The stock has a market capitalization of $5.94, a price-to-earnings ratio of -0.07 and a beta of 0.77. ImmunoCellular Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $3.68.

ImmunoCellular Therapeutics (NYSEAMERICAN:IMUC) last issued its quarterly earnings results on Tuesday, November 21st. The biotechnology company reported ($0.40) earnings per share for the quarter.

WARNING: “ImmunoCellular Therapeutics Ltd (IMUC) Short Interest Update” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit